

Hepatitis C Health Summary

Name: _____

DOB: _____

Phone #: _____

Alternate Contact: _____

Medications²:

Allergies:

Labs Prior to Treatment:

- Immediately prior: Pregnancy test
- Uric Acid (ribavirin only)
- Within 1 month: CBC with differential
- CMP (If GFR <30, do not start tx ¹)
- PT/INR
- HCV RNA
- Within 3 months: Genotype confirmation
- HBV DNA (if HBV cAb or sAg +)
- Within 6 months: AFP
- TSH
- A1C or Fasting Glucose
- Vitamin D 25OH
- Within 1 year: HIV screening
- NS5A RAV (genotype 3 only)
- Once: IL-28b (if considering 8 weeks)

Pertinent Medical History:

- Previous hepatitis C treatment¹ Yes No
Specify: _____
- Cirrhosis¹ Yes No
Child-Pugh Score: _____
- Other Liver Disease¹ Yes No
Specify: _____
- Pulmonary Disorders¹ Yes No
Specify: _____
- Cardiac Disease² Yes No
Specify: _____
- DVT or PE¹ Yes No
Specify: _____
- PPI/H2 blocker/Antacid use² Yes No
Specify: _____
- Autoimmune Disorders² Yes No
Specify: _____
- Cancer Yes No
Specify: _____
- Current infection¹ Yes No
Specify: _____
- High Blood Pressure Yes No
- High Cholesterol Yes No
- Kidney Disease² Yes No
- Anemia^{1,2} Yes No
- Current TB Treatment² Yes No
- Diabetes Specify Type 1 or 2 Yes No
- HIV or AIDS¹ Yes No
- Seizure Disorder² Yes No
- Depression/Anxiety Yes No
- Other Psychiatric Conditions Yes No
Specify: _____

Screen & Review: AUDIT-C ___ PHQ-9 ___
 Vaccine Status (give if needed):
 Hepatitis A ___ (If unknown, check hep A total IgG)
 Hepatitis B ___ (If unknown, check HBsAg & HBsAb)

- Other vaccines as appropriate:
- Flu (annually)
 - PCV-13 (≥ age 65 or immunosuppressed)
 - PPSV-23 (≥ age 50 AN/AI in AK or high risk)
 - Td (once every 10 years) **OR** Tdap (once)
 - Zoster (≥ age 60)
 - ECG (over age 65 or h/o cardiac disease)

Birth Control: Birth Control Methods: _____
 Females: LMP: _____ Pregnant Yes No
 Males: Is your partner pregnant? Yes No
 Counsel about pregnancy prevention (see Treatment Agreement)
 Hepatitis C Treatment Agreement reviewed and signed

1- Further evaluation as indicated; consult Liver Disease Specialist prior to treatment.
 2- Check drug interactions to treatment drugs. Further evaluation as indicated.



ALASKA NATIVE
TRIBAL HEALTH
CONSORTIUM

Liver Disease & Hepatitis Program
4315 Diplomacy Drive, Anchorage, AK 99508
Phone: 907-729-1560 Fax: 907-729-1570

<http://www.anthc.org/hep>

Follow us on Twitter:

Liver Program @ANTHCLiver

We are glad to hear you are interested in treatment for hepatitis C!

Here are some things to think about (and do) before you make your final decision about treatment:

Why do treatment now? New medicines have increased the chance of cure and have fewer side effects.

Some people have worse liver disease than others. If you have more severe liver disease (a lot of scarring in the liver or cirrhosis) you should consider getting treatment sooner.

What will happen during treatment?

There are 6 FDA approved treatment options for **genotype 1**:

- Option 1 is Harvoni® (ledipasvir/sofosbuvir), 1 tablet taken once a day for 8-24 weeks. The most common side effects are feeling tired and headache. In clinical studies, treatment response rates to Harvoni® were 94-100%.
- Option 2 is Epclusa® (sofosbuvir/velpatasvir), 1 tablet taken once a day for 12 weeks. The most common side effects are headache and feeling tired. In clinical studies, treatment response rates to Epclusa® were 94-98% for genotype 1.
- Option 3 is Viekira Pak™ (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) co-packaged as 3 tablets in the morning and 1 tablet in the evening with food for 12-24 weeks. The major side effects are nausea, itching, and insomnia. In clinical studies, response rates to Viekira Pak™ treatments were 86-100%.
- Option 4 is Zepatier™ (elbasvir/grazoprevir), 1 tablet taken once a day for 12-16 weeks. The most common side effects are feeling tired, nausea, and headache. In clinical studies, treatment response rates to Zepatier™ were 95-100%.
- Option 5 is Olysio® (simeprevir) plus Sovaldi® (sofosbuvir) 1 tablet of each taken once daily for 12 weeks. The most common side effects are feeling tired, headache, and nausea. In clinical studies, treatment response rates to Olysio® and Sovaldi® were 86-100%.
- Option 6 is Daklinza™ (daclatasvir) plus Sovaldi® (sofosbuvir) 1 tablet of each taken once daily for 12 weeks. The most common side effects are headache and feeling tired. In clinical studies, treatment response rates to Daklinza™ and Sovaldi® were 50-100%.

The FDA-approved **Genotype 2** treatment is Epclusa® (sofosbuvir/velpatasvir), 1 tablet taken once a day for 12 weeks. The major side effects are headache and feeling tired. In clinical studies, the treatment response rate to Epclusa® was 99% for genotype 2.

There are 2 FDA-approved treatment options for **genotype 3**:

- Option 1 is Epclusa® (sofosbuvir/velpatasvir), 1 tablet taken once a day for 12 weeks. The most common side effects are headache and feeling tired. In clinical studies, treatment response rates to Epclusa® were 85-98% for genotype 3.
- Option 2 is Daklinza™ (daclatasvir) and Sovaldi® (sofosbuvir) 1 tablet of each taken once daily for 12 weeks. The most common side effects are headache and feeling tired. In clinical studies, treatment response rates for Daklinza™ and Sovaldi® were 58-98%.

Some treatments will require ribavirin which is 5-6 additional tablets divided between morning and evening with food. The major side effects are feeling tired, nausea, itching and skin rash, trouble sleeping, irritability and weakness. A common side effect of ribavirin is anemia.

PLEASE NOTE: Ribavirin cannot be given to a pregnant or breastfeeding female or to a female who plans to become pregnant or a male who plans to father a child during or for 6 months after treatment because it can cause birth defects. There are no studies on Harvoni®, Epclusa®, Sovaldi®, Viekira Pak™, Zepatier™, or Daklinza™ in pregnant women or nursing mothers. Safety/risk during pregnancy or breastfeeding has not been established.

Are you ready for treatment?

To ensure that you will be successful in completing hepatitis C treatment we ask that the following items be done before starting treatment. We will review them together.

- You must be alcohol and drug-free. If you have recent drug/alcohol abuse, you need to be in an approved drug treatment program.
- You need to discuss hepatitis C treatment with your primary care provider and get his or her "OK" to start treatment.
- You should have a relative/close friend who is willing to help support you during treatment.
- You need to be committed to making every treatment appointment and getting **FREQUENT** blood draws (every 1-4 weeks). We will want to follow you very closely during treatment.

Additional Requirements If Checked:

_____ If you have cirrhosis, you may need an EGD (when a doctor looks into your esophagus and stomach for swollen veins that can bleed).

_____ If you have cirrhosis, you need to have an ultrasound of the liver (done in the past 6 months). This ultrasound checks your liver for cancer.

Once everything you need to do on the list has been done, call your primary care provider to make an appointment to plan for hepatitis C treatment. At this appointment, treatment and side effects will be discussed in detail.

If you are coming to Anchorage and want a Fibroscan, call the Liver Clinic ahead of your visit to schedule. Fibroscan is a test using ultrasound waves to check liver stiffness or scarring/fibrosis in your liver. Fibroscan testing is done in the Internal Medicine Clinic. Do not eat or drink for 3 hours before the test.

Congratulations on completing all the pre-treatment requirements!

Hepatitis C Treatment Checklists

Prior to Treatment

Labs

- | | |
|--|---|
| <p>Immediately prior: ___ Pregnancy test (if applicable)</p> <p style="padding-left: 20px;">___ Uric Acid (with ribavirin)</p> <p>Within 1 month: ___ CBC with differential</p> <p style="padding-left: 20px;">___ CMP¹</p> <p style="padding-left: 20px;">___ PT/INR</p> <p style="padding-left: 20px;">___ HCV RNA</p> <p>Within 3 months: ___ Genotype confirmation</p> <p style="padding-left: 20px;">___ HBV DNA (if HBV cAb or sAg +)</p> <p>Within 6 months: ___ AFP</p> <p style="padding-left: 20px;">___ TSH</p> <p style="padding-left: 20px;">___ A1C or Fasting Glucose</p> <p style="padding-left: 20px;">___ Vitamin D 25OH (treat if deficient)</p> <p>Within 1 year: ___ HIV screening</p> <p style="padding-left: 20px;">___ NS5A RAV (genotype 3 only)</p> <p>Once: ___ IL-28b (if considering 8 weeks)</p> | <p>Miscellaneous:</p> <p>___ Hepatitis A (If vaccine status is unknown, draw HAV total)</p> <p>___ Hepatitis B (If vaccine status is unknown, draw HBsAg & HBsAb)</p> <p>___ PHQ-9 baseline</p> <p>___ AUDIT-C</p> <p>___ Counsel about pregnancy prevention</p> <p>___ Review & sign Treatment Agreement</p> |
|--|---|

8 week

Week 4

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Week 8

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

12 week

Week 2 (with ribavirin)

- ___ CBC
- ___ CMP¹

Week 4

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Week 8

- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Week 12

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

16 week

Week 2 (with ribavirin)

- ___ CBC
- ___ CMP¹

Week 4

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Weeks 8 & 12

- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Week 16

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

24 week

Week 2 (with ribavirin)

- ___ CBC
- ___ CMP¹

Week 4

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Weeks 8, 12, 16, & 20

- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Week 24

- ___ HCV RNA
- ___ CBC
- ___ CMP¹
- ___ Pregnancy test

Nurse follow-up in clinic or by phone:

- ___ Managing side effects
- ___ Medication adherence discussion
- ___ Alcohol intake
- ___ Birth control reminder
- ___ Refill reminder

3 months post treatment

- ___ CBC
- ___ Liver Function Tests
- ___ HCV RNA
- ___ AUDIT-C

6 months post treatment

- ___ HCV RNA
- ___ AFP
- ___ RUQ US (if advanced fibrosis)
- ___ AUDIT-C

1- Sofosbuvir- or daclatasvir-based regimen - If GFR <30, no safe recommendation.

With ribavirin - If GFR <50, decrease dose (refer to package insert).

Daklinza™ (Daclatasvir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Agreement

Family Medicine Provider: _____

If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask any questions you may have before you sign the form.

In July 2015 the FDA approved daclatasvir (Daklinza™) in combination with sofosbuvir (Sovaldi®) for the treatment of hepatitis C genotypes 1 and 3. In some circumstances, it has been found that the treatment works better when given with ribavirin.

Treatment with daclatasvir, sofosbuvir, and ribavirin requires approximately 6 scheduled visits over 6 months for a 12-week treatment course and 10 scheduled visits over 9 months for the 24-week treatment course.

PREGNANCY & BREASTFEEDING WARNING

Ribavirin can harm an unborn child or breastfeeding infant. A woman must not get pregnant and a man must not father a child while taking ribavirin or for 6 months after treatment. You must **use 2 forms of birth control** when you take ribavirin and for 6 months after your last dose.

Acceptable Birth Control Methods (must use 2):

- Birth control pills or other hormone containing birth control
- Male or female condom
- Spermicides (creams, films, foams, gels, and/or suppositories)
- Diaphragm or cervical cap
- Intrauterine device (IUD), Today® vaginal sponge

Unacceptable Birth Control Methods:

- Rhythm method or withdrawal

HOW THE TREATMENT PROCESS WORKS

You will have blood and urine tests.

- These tests will include a pregnancy test for female patients of childbearing age. Urine pregnancy tests will be done monthly during clinic visits. If you are a woman and your treatment includes ribavirin it is recommended that you continue monthly home pregnancy testing for 6 months after treatment and notify your healthcare provider if you become pregnant. Female partners of males whose treatment includes ribavirin should do a monthly home pregnancy test during treatment and for 6 months after treatment completion and notify their health care provider if they become pregnant.
- Random drug and alcohol tests may be requested.
- At each visit, about 2-3 tubes of blood will be collected. Other examinations and tests may be done during the treatment if your provider feels there is a need.

Provider, select the appropriate length and rationale for treatment course of daclatasvir, sofosbuvir, plus ribavirin

___ will be treated for 12 weeks

- you have genotype 1 or 3 with decompensated (severe) cirrhosis

___ will be treated for 24 weeks

- You have genotype 3 without cirrhosis and previous treatment with sofosbuvir/ribavirin failed
- You have genotype 3 with compensated cirrhosis and previous treatment with sofosbuvir and ribavirin or peginterferon and ribavirin failed.
- You have genotype 3 and compensated cirrhosis

Your first three visits will be at the start of treatment (week 0) and weeks 2 and 4 after you begin taking the medications. After that, the visits will be once each month until you stop taking the medications.

You may need to see your primary care provider more frequently if you are having side effects or problems related to the treatment.

You will have a clinic visit 3 months after treatment completion and then yearly (corresponding to your end of treatment date) for 5 years. If you have cirrhosis you should continue to have a liver ultrasound and alpha fetoprotein (AFP) cancer screening blood test every six months and regular clinic visits.

TREATMENT MEDICATIONS AND SIDE EFFECTS

Daclatasvir is a 60 mg tablet. You will take daclatasvir once daily by mouth with or without food. Store daclatasvir at room temperature. If you miss a dose of daclatasvir, take the missed dose as soon as you remember the same day. Do not take more than 1 tablet of daclatasvir in a day. Take your next dose of daclatasvir at your regular time the next day.

- The most common side effects are headache and tiredness.

Tell your healthcare provider if you are taking any of the following medicines, as they are contraindicated with daclatasvir:

- Rifampin (Rifadin[®], Rifamate[®], Rifater[®], Rimactane[®])
- St. John's wort (hypericum perforatum)
- Phenytoin (Dilantin[®], Phenytek[®]), carbamazepine (Carbatrol[®], Epitol[®], Equetro[®], Tegretol[®])

Tell your healthcare provider if you are taking any of the following medicines, as they are not recommended to be used with daclatasvir:

- Amiodarone (Cordarone[®], Nexterone[®], Pacerone[®])
- Dabigatran etexilate mesylate (Pradaxa[®]); in renal impairment, refer to prescribing information.

Tell your healthcare provider if you are taking any of the following medicines, as they require dose adjustment and/or monitoring:

Drugs that require daclatasvir dose reduction to 30mg:

- Atazanavir/ritonavir (Reyataz[®])
- Indinavir (Crixivan[®])
- Nelfinavir mesylate (Viracept[®])

- Saquinavir mesylate (Invirase®)
- Cobicistat-containing antiretroviral regimens (except darunavir/cobicistat)
- Clarithromycin (Biaxin®)
- Telithromycin (Ketek®)
- Itraconazole (Onmel®, Sporanox®)
- Ketoconazole
- Posaconazole (Noxafil®)
- Voriconazole (Vfend®)
- Nefazodone (Serzone®)

Drugs that require daclatasvir dose increase to 90mg:

- Efavirenz (Sustiva®); Etravirine (Intelence®)
- Nevirapine (Viramune®)
- Nafcillin
- Bosentan (Tracleer®)
- Dexamethasone (Decadron®)
- Modafinil (Provigil®)
- Rifapentine (Priftin®)

Drugs that are moderate CYP3A inhibitors and require monitoring for side effects or drug level*:

- Digoxin (Lanoxicaps®, Lanoxin®) – *Dose reduction recommended and monitor digoxin level while on treatment
- Buprenorphine (Buprenex®, Butrans®, Belbuca™, Subutex®)
- Buprenorphine/Naloxone (Zubsolv®, Bunavail®, Suboxone®)

HMG-CoA Reductase Inhibitors require monitoring for side effects such as myopathy:

- Atorvastatin (Lipitor®); Fluvastatin (Lescol®); Pitavastatin (Livalo®)
- Pravastatin (Pravachol®); Rosuvastatin (Crestor®); Simvastatin (Zocor®)

Sofosbuvir is a 400mg tablet. You will take sofosbuvir once daily by mouth with or without food. Store sofosbuvir at room temperature. If you miss a dose, take the missed dose as soon

as you remember the same day. Do not take more than 1 tablet of sofosbuvir in a day. Take your next dose of sofosbuvir at your regular time the next day.

- Most common side effects are feeling tired, headache.

Tell your healthcare provider if you are taking any of the following medicines:

- Amiodarone (Cordarone[®], Nexterone[®], Pacerone[®])
- Carbamazepine (Carbatrol[®], Epitol[®], Equetro[®], Tegretol[®])
- Oxycarbazepine (Trileptal[®], Oxtellar XR[®])
- Phenytoin (Dilantin[®], Phenytek[®])
- Phenobarbital (Luminal[®]); Primidone (Mysoline[®])
- Rifabutin (Mycobutin[®])
- Rifampin (Rifadin[®], Rifamate[®], Rifater[®], Rimactane[®])
- Rifapentine (Priftin[®])
- St. John's wort (*Hypericum perforatum*) or a product that contains St. John's wort
- Tipranavir (Aptivus[®])

Ribavirin is a 200mg capsule or tablet. You will take ribavirin pills twice daily by mouth with food (dose is based on your weight). You should not miss/skip taking any pills. **A common side effect is anemia.** Anemia is a condition where the blood has a decreased number of red blood cells. This occurs more often in older persons taking ribavirin. Anemia can be serious in patients who have kidney problems. In patients who have coronary artery disease (narrowing of the blood vessels in the heart), anemia may make the problem worse, leading to chest pain or heart attack. If your provider believes you may have coronary artery disease, you will be tested for this and excluded from treatment if it is serious.

- Other common side effects include: headache, trouble sleeping, nausea, vomiting, weakness or lack of energy, shortness of breath, loss of appetite, itching, cough, muscle pain, swelling and pain in your joints (gout), depression, nervousness, and dizziness.
- Studies in animals have shown when ribavirin is given to pregnant females, death of the developing embryo or birth of deformed baby animals may result. It is expected that similar results as seen in the animal studies could occur in humans.

PLEASE NOTE

You must let your medical, mental health, dental providers, and pharmacist(s) know that you are taking daclatasvir and sofosbuvir prior to starting any new medications. You must let your providers know about any new medications you are prescribed before starting them. This includes vitamins and other supplements.

***Hepatitis C treatment should not cause pain that requires narcotic pain medication.

BENEFITS OF TREATMENT

In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks **after** the end of treatment, this is called a “sustained virologic response” and means you no longer have hepatitis C. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment.

It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time.

In Studies:

Persons who were genotype 1 with decompensated (severe) cirrhosis who were treated with daclatasvir and sofosbuvir with ribavirin for 12 weeks had a response rate of 83%. The response rate in those who were Child-Pugh B was 94% and in those whose cirrhosis was Child-Pugh C the response was 56%. Those who had Genotype 3 with decompensated cirrhosis had an 83% response.

Persons with genotype 3 who had compensated (mild) cirrhosis were treated with daclatasvir and sofosbuvir for 12 weeks and had a 58% response. The European compassionate-use program treated persons with genotype 3 and cirrhosis for 24 weeks with daclatasvir and sofosbuvir and had an 86% response. Pending further data treatment extension and the addition of ribavirin is recommended.

Persons with genotype 3 without cirrhosis who had previous treatment with sofosbuvir plus ribavirin that failed were treated with daclatasvir and sofosbuvir for 12 weeks and had a 71% response. Based on this limited data it is recommended to extend treatment duration to 24 weeks and add ribavirin.

There is limited data for retreating persons with genotype 3 and cirrhosis whose previous treatment has failed. Genotype 3 cirrhotic patients given daclatasvir and sofosbuvir with ribavirin for 12 or 16 weeks had an 88% and 89% response rate. Therefore, it is recommended that persons with genotype 3 and compensated (mild) cirrhosis whose previous treatment with sofosbuvir plus ribavirin or peginterferon and ribavirin failed receive daclatasvir plus sofosbuvir and ribavirin for 24 weeks pending additional data.

WHOM TO CALL

If you have any questions about your treatment, contact your primary care provider.

TREATMENT AGREEMENT

To receive treatment, please review the following statements and initial beside the responses:

_____ I agree not to drink alcohol or use recreational drugs during the treatment.

_____ I will tell my provider if I have any serious medical conditions (such as heart disease, high blood pressure, diabetes, high cholesterol, rheumatoid arthritis, or drug addiction), or psychiatric conditions (depression, history of suicide attempts, bipolar disorder, or psychosis).

_____ I am willing to visit the clinic and see a provider on a regular schedule for the entire length of the treatment. If I am unable to attend an appointment, I will let my provider know this ahead of time and I will reschedule my appointment.

_____ I understand that my treatment will be stopped if I cannot attend appointments as required to evaluate my health and well-being during treatment and the effectiveness of treatment.

_____ I will use 2 acceptable methods of birth control during treatment and for 6 months after I stop treatment (see lists, page 1).

_____ As a female, I understand that I cannot be pregnant or breastfeeding during the treatment and for 6 months after treatment. I understand that my treatment will be stopped if I become pregnant. _____ Not applicable, I am surgically sterile or post-menopausal.

_____ As a male taking ribavirin I understand that I should not father a child during treatment and for 6 months after treatment.

_____ If I have any problems with the medications or side effects that bother me, I will let my provider or nurse know right away.

_____ I understand that my hepatitis C may not respond to treatment.

_____ I understand that my provider can stop my treatment if the provider feels that stopping it is in the best interest of my health and welfare.

_____ I will do my best to take my medications as prescribed by my provider. If I am unable to do so, I will contact my provider.

_____ I will protect myself and others from hepatitis C by not sharing needles, toothbrushes, razors or nail clippers and covering cuts to prevent blood exposure.

My signature below means that I have read this treatment agreement and/or the meaning of the information has been explained to me. I agree to treatment.

Patient’s Name (PLEASE PRINT) Patient’s Signature Date

Provider’s Name (PLEASE PRINT) Provider’s Signature Date

Daklinza™ (Daclatasvir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Medications

You will be taking the following medications:

1. Daklinza™ 60mg tablet

Take ONE tablet by mouth daily, with or without food.

The generic name for Daklinza™ is Daclatasvir 60mg. (Also available in 30mg and 90mg tablets).

2. Sovaldi® 400mg tablet

Take ONE tablet by mouth daily, with or without food.

The generic name for Sovaldi® is Sofosbuvir.

- Do not take supplements or tea containing St. John’s wort while taking Sovaldi®.

3. Ribavirin 200mg capsules

Take ___ capsules in the morning **with food** and ___ capsules in the evening **with food**. The earlier in the evening you take ribavirin, the less likely you will have sleep problems.

You get _____ from _____.

You get _____ from _____.

Pick up refills on: _____

Call your provider if you feel you are having any significant side effects while taking these medications, or have any other questions about treatment.

Call _____ to schedule your family medicine treatment appointments, or if you have any other health concerns.

*****For any emergencies after normal business hours, please go to the Emergency Room. Make sure any healthcare provider you see knows you are on treatment. Carry a list of your medicines with you.**

For more information on managing side effects

visit: <http://www.anthctoday.org/community/hep/patients/index.html>

Click on “Patient Guide- Managing HepC Treatment”

Daklinza™ (Daclatasvir), Sovaldi® (Sofosbuvir), & Ribavirin 24 week Lab Tracking Form

General Patient Information

Name: _____
 DOB: ____/____/____
 MRN: _____
 Phone #: _____
 Treatment Start Date: _____

Pre-Treatment Lab Results

HCV RNA: _____ PHQ-9: _____
 Genotype: ____ HIV: ____ TSH: _____
 AFP: ____ Vit D 25OH: _____ GFR*: _____
 PT/INR: _____ A1C/Glucose: _____
 Uric Acid: _____

Medication Regimen

1- Daclatasvir 60mg daily
 1 tablet daily. Consult Liver Disease providers prior to dose change.
 2- Sofosbuvir 400mg daily.
 1 tablet daily. Do not change dose
 3- Ribavirin _____ mg/day PO divided into 2 doses.
 ≥75kg = 1200mg/day <75kg = 1000mg/day
 **Dose Reduction/Date: _____/_____
 **Additional Dose Change/Date: _____/_____
 **Consult ANTHC Liver Disease & Hepatitis Specialists for further guidance about dose

Completed Treatment Week	Lab Date	Hgb	Hct	WBC	PLT	ALT	AST	Alk Phos	Total Bili	Creat/ GFR	HCV RNA (Specified weeks)	Weight (kg)	Pregnancy Test
Pre-Treatment													
Treatment Start Week 0											HCV RNA		
<i>optional</i>													
Week 2													
<i>optional</i>													
Week 4											HCV RNA		
<i>optional</i>													
<i>optional</i>													
Week 8													
<i>optional</i>													
<i>optional</i>													
Week 12											HCV RNA		
<i>optional</i>													
Week 16													
<i>optional</i>													
Week 20													
<i>optional</i>													
Week 24											HCV RNA		
3 months post treatment											HCV RNA		

Labs recommended for each follow up visit: CBC, CMP, pregnancy test (females of childbearing age), and HCV RNA as specified.

Please note the following critical values. These may require modification of dosage or discontinuation of causative med. Contact ANTHC Liver Disease Specialists with any questions.

*GFR <30 If GFR is <30, do not start treatment; consult with Liver Disease Specialists.

Hgb <10.0 gm/dL If hemoglobin drops below 10, reduce ribavirin dose to 600mg (refer to ribavirin package insert). If hemoglobin <8.5, hold ribavirin & consult ANTHC Liver Disease Specialists.

GFR <50 If GFR is <50, decrease ribavirin dose (refer to ribavirin package insert) and consult ANTHC Liver Disease Specialists.

Please Remember

Give the End of Treatment Letter to the patient at the completion of treatment.

End of Treatment Letter is found in Treatment Monitoring section on webpage.

12 weeks after treatment completion obtain an HCV RNA to check for a sustained virologic response (SVR). SVR is considered a virologic cure of hepatitis C.

SVR12 Cure Letter is found in Treatment Monitoring section on webpage.

<http://anthctoday.org/community/hep/providers/treatment/index.html>